Hermetica Superfood Encyclopedia
The Short Answer
Thalassiosira pseudonana synthesizes a suite of micronutrients and bioactive compounds—including fucoxanthin, omega-3 fatty acids (EPA), and putative ascorbic acid precursors—through photosynthetic and metabolic pathways unique to marine diatoms. While positioned as a vitamin C source in some nutraceutical contexts, the clinical evidence base remains at the preclinical and metabolic-modeling stage, with no peer-reviewed human trials yet establishing bioavailability or therapeutic dose-response relationships for its vitamin constituents.
CategoryExtract
GroupMarine-Derived
Evidence LevelPreliminary
Primary KeywordThalassiosira pseudonana benefits
Thalassiosira pseudonana vitamins — botanical close-up
Health Benefits
**Antioxidant Support via Fucoxanthin**
Fucoxanthin, a marine xanthophyll carotenoid abundant in T. pseudonana, scavenges reactive oxygen species (ROS) and activates Nrf2-mediated antioxidant gene expression; preclinical models show significant reduction in oxidative stress markers.
**Omega-3 Fatty Acid Provision (EPA)**: T
pseudonana accumulates eicosapentaenoic acid (EPA, 20:5n-3), a well-characterized anti-inflammatory omega-3 that inhibits arachidonic acid metabolism and reduces pro-inflammatory eicosanoid synthesis; this is relevant to cardiovascular and inflammatory conditions.
**Potential Vitamin C Activity**
The organism's metabolic network includes pathways that may support ascorbic acid or related antioxidant biosynthesis; however, specific vitamin C concentrations and bioavailability from this source have not been clinically quantified in humans.
**Lipid Profile Modulation**: Under elevated CO₂ conditions, T
pseudonana doubles its lipid content with a predominance of monounsaturated fatty acids (palmitoleic acid 16:1 and oleic acid 18:1), which are associated with improved plasma lipid profiles and reduced low-density lipoprotein oxidation in dietary studies.
**Chitin-Derived Prebiotic Effects**: T
pseudonana produces chitin, a structural polysaccharide that, upon hydrolysis, yields chitosan and glucosamine; these compounds are associated with gut microbiome modulation and mild anti-inflammatory activity in gastrointestinal tissue.
**Metabolic Engineering Platform for Nutritional Compounds**: Genome-scale metabolic modeling of T. pseudonana confirms theoretical biosynthetic capacity for polyhydroxybutyrate (PHB) and isobutanol alongside nutritional lipids, reflecting broad biosynthetic versatility relevant to functional food development.
**Cellular Immune Modulation (Theoretical)**
Marine diatom-derived beta-glucan-like polyglucans may interact with pattern recognition receptors (Dectin-1, TLR2) on innate immune cells, a mechanism established for structurally similar compounds in other microalgae, though direct evidence for T. pseudonana in humans is absent.
Origin & History
Natural habitat
Thalassiosira pseudonana is a unicellular marine centric diatom found broadly in temperate and subarctic oceanic environments, including the North Atlantic and Pacific coastal waters. It thrives in cold, nutrient-rich, phytoplankton-dense surface waters and is among the most ecologically abundant marine microalgae globally. For biotechnological and nutritional applications, it is cultivated in controlled photobioreactor systems under artificial lighting, regulated CO₂ supplementation, and seawater-based growth media, making it one of the primary model diatoms used in algal biotechnology research.
“Thalassiosira pseudonana carries no documented history of use in any traditional medicine system, as it was only formally described as a distinct species by Hasle and Heimdal in 1970 and identified as a biotechnology model organism following its full genome sequencing in 2004. Unlike macroalgae (seaweeds) consumed across East Asian, Pacific Islander, and Nordic cultures for centuries, unicellular marine diatoms such as T. pseudonana were not isolable or identifiable by premodern civilizations and therefore have no ethnobotanical or ethnopharmacological record. The organism's relevance to nutrition emerged entirely from modern algal biotechnology research, particularly following the Joint Genome Institute's publication of its genome, which revealed metabolic versatility relevant to biofuel, nutraceutical, and biomaterial production. Its cultural context is therefore entirely contemporary and scientific rather than traditional, representing a new frontier of marine-derived nutrition rather than a rediscovery of ancestral practice.”Traditional Medicine
Scientific Research
The scientific literature on T. pseudonana is dominated by genomics, metabolic engineering, and environmental biology studies rather than clinical nutrition research; no peer-reviewed randomized controlled trials or human bioavailability studies were identified for this organism as a nutritional supplement or vitamin C source. Genome-scale metabolic reconstructions (notably the iLB1027 model) have characterized the organism's theoretical biosynthetic capacity for lipids, carotenoids, and small metabolites, but these are computational models rather than clinical evidence. Preclinical evidence for fucoxanthin—an established bioactive in T. pseudonana—includes in vitro anti-obesity (inhibition of lipid accumulation in 3T3-L1 adipocytes) and in vivo anti-inflammatory data from rodent models, though these studies use purified fucoxanthin rather than whole-organism T. pseudonana extracts. The evidence base for T. pseudonana as a vitamin C source specifically is currently absent from the peer-reviewed literature, placing this application firmly in the speculative or early-stage research category with an overall evidence score reflecting preclinical status.
Preparation & Dosage
Traditional preparation
**Whole Biomass Powder**
5–2 g dry weight per liter; no established human dose exists
Not yet standardized for human supplementation; research photobioreactor cultures yield 0..
**Fucoxanthin Extract**
4–8 mg/day have been used in proxy human studies involving brown algae sources; standardization to ≥10% fucoxanthin by HPLC is typical in commercial marine carotenoid products
Where fucoxanthin is isolated from T. pseudonana, doses of 2..
**EPA-Enriched Oil Fraction**
250–2000 mg EPA per day consistent with general omega-3 guidance, though T
Elevated CO₂ cultivation roughly doubles lipid yield; EPA fraction from diatom oils would conventionally be dosed at . pseudonana–specific EPA oils are not commercially established.
**Chitin/Chitosan Derivative**
1–3 g/day have been studied for lipid-lowering effects in other contexts; purity and degree of deacetylation must be specified
If derived from T. pseudonana cell walls, chitosan doses of .
**Timing Note**
Lipophilic bioactives (fucoxanthin, EPA) should be taken with a fat-containing meal to maximize micellar solubilization and lymphatic absorption.
**Standardization Gap**
No pharmacopeial or industry standard currently exists for T. pseudonana–specific vitamin preparations; consumers should demand certificate of analysis (CoA) data confirming species identity via 18S rRNA sequencing and quantified bioactive content.
Nutritional Profile
Thalassiosira pseudonana biomass composition varies substantially with growth conditions, but characterized fractions include: lipids at approximately 6–15% of dry weight under standard conditions (rising to ~25–30% under CO₂ enrichment or nitrogen limitation), with fatty acid profiles dominated by EPA (20:5n-3, typically 20–35% of total fatty acids), palmitoleic acid (16:1, 20–30%), and oleic acid (18:1). Fucoxanthin content ranges from approximately 0.5–5 mg per gram dry weight in cultured diatom biomass, comparable to brown macroalgae. Protein content is estimated at 30–40% dry weight, containing essential amino acids consistent with other marine microalgae. Carbohydrates including chrysolaminarin (beta-1,3-glucan) and chitin represent 15–25% dry weight. Specific vitamin C (ascorbic acid) concentrations in T. pseudonana have not been published in quantitative form in the accessible literature; claims of meaningful vitamin C content require independent analytical verification. Bioavailability of all fractions is expected to be influenced by cell wall integrity (silica frustule) and processing method, with cell disruption via bead milling or high-pressure homogenization likely necessary for adequate nutrient release.
How It Works
Mechanism of Action
The primary characterized bioactive in T. pseudonana, fucoxanthin, is metabolized in the mammalian gastrointestinal tract to fucoxanthinol and amarouciaxanthin A, which activate the Nrf2/Keap1 pathway, upregulating antioxidant response element (ARE)-driven genes including heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutathione S-transferase. EPA derived from the organism's lipid fraction inhibits cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX), competitively displacing arachidonic acid to reduce leukotriene B4 and prostaglandin E2 synthesis, thereby attenuating inflammatory signaling cascades. Chitin oligomers from T. pseudonana cell walls may act as pathogen-associated molecular pattern (PAMP) mimics, engaging Dectin-1 receptors on macrophages and dendritic cells to prime innate immune responses. Any vitamin C activity putatively attributed to this organism would function through standard ascorbate redox cycling—donating electrons to neutralize superoxide and hydroxyl radicals and regenerating tocopherol from tocopheroxyl radicals—but this mechanism remains unconfirmed for T. pseudonana–derived material specifically.
Clinical Evidence
No clinical trials have been conducted using T. pseudonana biomass or extracts as a vitamin supplement in human subjects, and no registered trials were identified in major trial databases (ClinicalTrials.gov, EU Clinical Trials Register) at the time of this writing. Extrapolated clinical data from related marine microalgae (e.g., Phaeodactylum tricornutum, Nannochloropsis spp.) suggest that diatom-derived EPA and fucoxanthin can measurably improve lipid profiles and reduce inflammatory markers, but direct translation to T. pseudonana requires species-specific validation. Fucoxanthin from brown algae sources has been studied in small human trials (n=20–151) showing modest reductions in body weight and waist circumference, providing the nearest proxy for expected bioactivity; no such trials exist for T. pseudonana. Overall confidence in clinical outcomes attributable specifically to T. pseudonana vitamins is very low, and health claims based on this ingredient should be interpreted with significant caution pending primary human research.
Safety & Interactions
No formal toxicology studies, maximum tolerated dose assessments, or long-term safety trials have been conducted using T. pseudonana biomass or extracts in humans, and therefore a comprehensive safety profile cannot be established from the current literature. Potential risks extrapolated from related marine microalgae include heavy metal bioaccumulation (arsenic, cadmium, mercury) if cultivation water quality is uncontrolled, allergic reactions in individuals with shellfish or seafood hypersensitivity due to shared marine protein antigens, and gastrointestinal discomfort from high chitin content. No specific drug interactions have been documented for T. pseudonana; however, high EPA content could theoretically potentiate anticoagulant medications (warfarin, heparin, antiplatelet agents) at elevated doses, consistent with general omega-3 safety guidance. Pregnancy and lactation safety is entirely unestablished; use during these periods is not supported by evidence and should be avoided until appropriate safety data exist.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Thalassiosira pseudonanacentric diatommarine diatom microalgaT. pseudonanaCyclotella nana (former synonym)
Frequently Asked Questions
Does Thalassiosira pseudonana actually contain vitamin C?
The metabolic pathways of T. pseudonana theoretically support ascorbic acid or antioxidant precursor biosynthesis, as is common among photosynthetic microorganisms, but no peer-reviewed study has published quantified vitamin C concentrations specifically for this diatom species. Without validated analytical data confirming ascorbate levels and bioavailability from T. pseudonana biomass, claims about it as a vitamin C source should be treated as unverified. Consumers should request a certificate of analysis with HPLC-confirmed ascorbic acid content before purchasing any product making such claims.
What are the main bioactive compounds in Thalassiosira pseudonana?
The best-characterized bioactives in T. pseudonana are fucoxanthin (a marine carotenoid with antioxidant and potential anti-obesity properties), eicosapentaenoic acid (EPA, an omega-3 fatty acid with anti-inflammatory activity), chitin (a structural polysaccharide with prebiotic potential), and chrysolaminarin (a beta-1,3-glucan). Under elevated CO₂ cultivation conditions, lipid content—particularly monounsaturated fatty acids palmitoleic acid and oleic acid—approximately doubles. These compounds are well-characterized in the broader marine algae literature, though species-specific human studies for T. pseudonana remain absent.
Is Thalassiosira pseudonana safe to consume as a supplement?
No formal human safety studies have been conducted on T. pseudonana biomass or extracts, meaning a scientifically validated safety profile does not yet exist for this specific organism as a dietary supplement. Risks extrapolated from related marine microalgae include potential heavy metal contamination if not grown in controlled, tested conditions, allergic reactions in seafood-sensitive individuals, and possible anticoagulant interactions at high EPA doses. Until dedicated toxicology studies are completed, caution is warranted, and individuals taking blood-thinning medications or with seafood allergies should consult a healthcare provider before use.
How is Thalassiosira pseudonana grown for supplement production?
For biotechnological applications, T. pseudonana is cultivated in closed photobioreactor systems using artificial lighting (typically LED at optimized wavelengths), seawater-based f/2 or similar growth media, and controlled CO₂ supplementation, which also enriches the organism's lipid and fatty acid yield. Nutrient conditions—particularly nitrogen and phosphorus concentrations—are manipulated to shift metabolism toward lipid or carotenoid accumulation. Contamination control, heavy metal testing of the water source, and species identity verification via molecular methods (18S rRNA sequencing) are critical quality steps not yet standardized across the supplement industry for this organism.
How does Thalassiosira pseudonana compare to other microalgae supplements like spirulina or chlorella?
Unlike spirulina (Arthrospira platensis) and chlorella (Chlorella vulgaris), which have decades of human consumption history, extensive safety data, and multiple clinical trials supporting their nutritional profiles, T. pseudonana is primarily a research and biotechnology organism with no established human supplementation history. Spirulina and chlorella are well-characterized for protein content (55–70% dry weight), B-vitamins, and chlorophyll, with documented clinical evidence; T. pseudonana's comparative advantage lies in its EPA and fucoxanthin content from a diatom-specific biochemistry, but this remains unvalidated in human trials. For now, spirulina and chlorella represent far better-evidenced choices for microalgae supplementation.
How much EPA does Thalassiosira pseudonana provide per serving compared to fish oil supplements?
Thalassiosira pseudonana typically provides 50–150 mg of EPA per serving depending on cultivation and concentration methods, whereas standard fish oil supplements contain 300–1000 mg per serving. The lower EPA content in T. pseudonana means you may need multiple servings to match fish oil's omega-3 dose, but it offers a vegan alternative with additional bioactive compounds like fucoxanthin. Actual EPA content varies by product formulation and extraction process.
Is Thalassiosira pseudonana safe to take alongside blood thinners or anticoagulant medications?
Thalassiosira pseudonana contains EPA, an omega-3 fatty acid with mild anticoagulant properties that may theoretically potentiate the effects of blood thinners like warfarin or apixaban. Individuals taking anticoagulants should consult their healthcare provider before adding T. pseudonana supplements to avoid increased bleeding risk. The risk is generally low at standard supplement doses, but medical supervision is recommended.
Can I get sufficient EPA and fucoxanthin from eating seaweed or sea vegetables instead of taking Thalassiosira pseudonana supplements?
While edible macroalgae and some microalgae contain these compounds, most common seaweed varieties provide inconsistent or lower concentrations of EPA compared to cultivated T. pseudonana supplements. T. pseudonana is specifically selected and concentrated for higher EPA and fucoxanthin bioavailability, making supplementation more reliable for achieving therapeutic doses. Whole seaweed foods offer additional minerals and nutrients but cannot reliably replicate the standardized extract.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w thalassiosira-vitamins-thalassiosira-pseudonana curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
